198 related articles for article (PubMed ID: 35266155)
1. A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for signal confirmation in early drug development.
Hermann RP; Rockey DC; Suzuki A; Merz M; Tillmann HL
Aliment Pharmacol Ther; 2022 Apr; 55(8):1028-1037. PubMed ID: 35266155
[TBL] [Abstract][Full Text] [Related]
2. Prevention of stroke in patients with atrial fibrillation.
Olsson SB; Halperin JL
Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
[TBL] [Abstract][Full Text] [Related]
3. A novel quantitative computer-assisted drug-induced liver injury causality assessment tool (DILI-CAT).
Tillmann HL; Suzuki A; Merz M; Hermann R; Rockey DC
PLoS One; 2022; 17(9):e0271304. PubMed ID: 36174069
[TBL] [Abstract][Full Text] [Related]
4. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
Diener HC;
Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
[TBL] [Abstract][Full Text] [Related]
5. Preventing stroke in atrial fibrillation: the SPORTIF programme.
Lip GY
Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():25-30. PubMed ID: 15812201
[TBL] [Abstract][Full Text] [Related]
6. Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials.
Ford GA; Choy AM; Deedwania P; Karalis DG; Lindholm CJ; Pluta W; Frison L; Olsson SB;
Stroke; 2007 Nov; 38(11):2965-71. PubMed ID: 17885258
[TBL] [Abstract][Full Text] [Related]
7. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study.
Petersen P; Grind M; Adler J;
J Am Coll Cardiol; 2003 May; 41(9):1445-51. PubMed ID: 12742279
[TBL] [Abstract][Full Text] [Related]
8. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
Olsson SB;
Lancet; 2003 Nov; 362(9397):1691-8. PubMed ID: 14643116
[TBL] [Abstract][Full Text] [Related]
9. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
Albers GW; Diener HC; Frison L; Grind M; Nevinson M; Partridge S; Halperin JL; Horrow J; Olsson SB; Petersen P; Vahanian A;
JAMA; 2005 Feb; 293(6):690-8. PubMed ID: 15701910
[TBL] [Abstract][Full Text] [Related]
10. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
Albers GW;
Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
[TBL] [Abstract][Full Text] [Related]
11. [SPORTIF III and V trials: a major breakthrough for long-term oral anticoagulation].
Kulbertus H
Rev Med Liege; 2003 Dec; 58(12):770-3. PubMed ID: 14978854
[TBL] [Abstract][Full Text] [Related]
12. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.
Akins PT; Feldman HA; Zoble RG; Newman D; Spitzer SG; Diener HC; Albers GW
Stroke; 2007 Mar; 38(3):874-80. PubMed ID: 17255547
[TBL] [Abstract][Full Text] [Related]
13. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
[TBL] [Abstract][Full Text] [Related]
14. Effect of ximelagatran and warfarin on stroke subtypes in atrial fibrillation.
Teitelbaum JS; von Kummer R; Gjesdal K; Kristinsson A; Gahn G; Albers GW;
Can J Neurol Sci; 2008 May; 35(2):160-5. PubMed ID: 18574928
[TBL] [Abstract][Full Text] [Related]
15. Trials and tribulations of non-inferiority: the ximelagatran experience.
Kaul S; Diamond GA; Weintraub WS
J Am Coll Cardiol; 2005 Dec; 46(11):1986-95. PubMed ID: 16325029
[TBL] [Abstract][Full Text] [Related]
16. HLA-DR7 and HLA-DQ2: Transgenic mouse strains tested as a model system for ximelagatran hepatotoxicity.
Lundgren H; Martinsson K; Cederbrant K; Jirholt J; Mucs D; Madeyski-Bengtson K; Havarinasab S; Hultman P
PLoS One; 2017; 12(9):e0184744. PubMed ID: 28934241
[TBL] [Abstract][Full Text] [Related]
17. Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?
Reiffel JA
Curr Opin Cardiol; 2004 Jan; 19(1):58-63. PubMed ID: 14688636
[TBL] [Abstract][Full Text] [Related]
18. Ximelagatran in prevention of cardiovascular events.
Molckovsky D; Boucher M
Issues Emerg Health Technol; 2004 Nov; (62):1-4. PubMed ID: 15565751
[TBL] [Abstract][Full Text] [Related]
19. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
Huisman MV; Bounameaux H
Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
[TBL] [Abstract][Full Text] [Related]
20. Ximelagatran for stroke prevention in atrial fibrillation.
Boos CJ; Lip GY
Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):551-63. PubMed ID: 16076267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
